Oncology Selling General Administrative from 2010 to 2024

TOIIW Stock  USD 0.01  0  10.71%   
Oncology Institute Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative will likely drop to about 67.6 M in 2024. During the period from 2010 to 2024, Oncology Institute Selling General Administrative regression line of quarterly data had mean square error of 814.7 T and geometric mean of  23,760,024. View All Fundamentals
 
Selling General Administrative  
First Reported
2010-12-31
Previous Quarter
115.3 M
Current Value
67.6 M
Quarterly Volatility
37.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 7.1 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 0.44, Dividend Yield of 0.0235 or PTB Ratio of 2.51. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Check out the analysis of Oncology Institute Correlation against competitors.
For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of The Oncology Institute over the last few years. It is Oncology Institute's Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Oncology Selling General Administrative Regression Statistics

Arithmetic Mean39,962,965
Geometric Mean23,760,024
Coefficient Of Variation94.13
Mean Deviation30,151,396
Median20,389,385
Standard Deviation37,617,894
Sample Variance1415.1T
Range119.4M
R-Value0.68
Mean Square Error814.7T
R-Squared0.47
Significance0.01
Slope5,738,594
Total Sum of Squares19811.5T

Oncology Selling General Administrative History

202467.6 M
2023115.3 M
2022119.7 M
202183.4 M
2020309.2 K
201929.6 M

About Oncology Institute Financial Statements

Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative115.3 M67.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.